key: cord-1030075-03cb5y79 authors: G Alshahawey, Mona; S El-Housseiny, Ghadir; S Elsayed, Noha; Y Alshahrani, Mohammad; Wakeel, Lamia M EL; M Aboshanab, Khaled title: New insights on mucormycosis and its association with the COVID-19 pandemic date: 2021-12-16 journal: Future science OA DOI: 10.2144/fsoa-2021-0122 sha: fbb8b9237ebe81dbe606fe8d958cc435e2ff3b49 doc_id: 1030075 cord_uid: 03cb5y79 COVID-19 continues to cause significant fatality worldwide. Glucocorticoids prove to play essential roles in COVID-19 management; however, the extensive use of steroids together with the virus immune dysregulation may increase the danger of secondary infections with mucormycosis, an angioinvasive fungal infection. Unfortunately, a definite correlation between COVID-19 and elevated mucormycosis infection cases is now clear worldwide. In this review, we discuss the historical record and epidemiology of mucormycosis as well as pathogenesis and associated host immune response, risk factors, clinical presentation, diagnosis and treatment. Special emphasis is given to its association with the current COVID-19 pandemic, including latest updates on COVID-19-associated mucormycosis cases globally, with recommendations for efficacious management. and internal transcribed spacer sequencing are the gold standards for its identification [28] . Case reports and case series are the source of most of the information forming the epidemiology of mucormycosis. In 2005, Roden et al. published the first extensive analysis [29] , which included 929 cases reported in the period 1940-2003. The review, although informative, included entomophthoramycosis cases. Jeong et al. later published a review using the PRISMA guidelines and including mucormycosis cases solely amounting to 851 cases reported in the period 2000-2017 [30] . Case series are limited by being obtained on a national level [31] or only in patients with certain diseases [32] . Another valuable source are registries, such as that constructed by the Working Group on Zygomycosis of the European Confederation of Medical Mycology (ECMM) and the International Society of Human and Animal Mycology (ISHAM) in 2004 (www.zygomyco.net), which published 230 case reports from Europe in 2011 [33] . The incidence of mucormycosis is rising internationally. A study in the USA documented an increase in the mucormycosis incidence in hematological malignancy patients from 0.006 cases/100 autopsies in 1989-1993 to 0.018 cases in 2004-2008 [34] . Prevalence has also been rising in Europe. A center in Switzerland reported an increased prevalence from 0.57 cases/100,000 admissions/year before 2003 to 6.3 cases/100,000 admissions/year after 2003, as a result of excessive voriconazole and caspofungin use [35] . In a population-based study in France, the prevalence rose from 0.7 cases/million in 1997 to 1.2/million in 2006 [31] . In Belgium, a rise from 0.019 cases/10,000 patient-days in 2000 to 0.148 cases/10,000 patient-days in 2009 was reported [36] . In Asia, a comparable increase in prevalence was stated in several studies. A retrospective study from Iran including 208 mucormycosis cases from 2008 to 2014 demonstrated a substantial rise from 9.7% in 2008 to 23 .7% in 2014 [37, 38] . A national survey on medical autopsies conducted in Japan reported an increase in Mucormycosis from 0.01% cases in 1969 to 0.16% cases in 1989 [39] . India reported an increase in mucormycosis cases from 24.7 cases per year (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) to 89 cases per year (2013-2015) at a single tertiary-care hospital [40] . The escalation of mucormycosis in India was also demonstrated by Chakrabarti et al. who issued 3 successive studies from the same center. Prevalence rose from 12.9 cases/year during 1990-1999 [41] to 35.6 cases/year during 2000-2004 [16] and then to 50 cases/year during 2006-2007 [42] . Scarce data is known about mucormycosis prevalence in the Arabian countries [43] . An annual rate of 0.2 cases/100,000 individuals has been reported in Iraq, Jordan and Algeria, and 1.2 cases/100,000 individuals were reported in Qatar [44, 45] . Eighteen patients were recognized in another retrospective study carried out at a tertiary care center in the Kingdom of Saudi Arabia from January 2013 to December 2019 [46] . In Lebanon, incidence has significantly risen from 0.47 cases/10,000 admissions in 2008 to 1.18 cases/10,000 admissions in 2017 [47] . From Egypt, Zaki et al. reported 10 cases of mucormycosis, all detected at the Ain Shams University Specialized Hospital in Cairo, Egypt, during 2010 [48] . Another retrospective study was carried out at the Children's Cancer Hospital, Cairo, Egypt, during 2007-2017 and recorded 3.2 cases/1000 pediatric cancer patient admission; 90% of the cases had hematological malignancies [49] . Recently, an article was published including analyzed cases of mucormycosis across the Middle East and North Africa region. Cases of proven or probable invasive mucormycosis were recognized from the FungiScope database and the medical literature. A total of 310 cases of mucormycosis were reported mostly from Iran (n = 74), Israel (n = 63) and Tunisia (n = 49). Others were reported from Lebanon (n = 28), Saudi Arabia (n = 28), Egypt (n = 20), Iraq (n = 11) and Qatar (n = 10), and other countries reported fewer than 10 cases. Reported cases rose from 23 before 1990 to 127 in the 2010s [50] . Lack of data in our region makes it difficult to compare the mucormycosis epidemiology to global studies. However, a few countries, such as Lebanon, are currently partaking in international registries on mucormycosis overseen by the ECMM, which is valuable in comparing epidemiological and clinical variations among different regions [43] . In a comparison between the economies of the countries affected by mucormycosis, it was found, surprisingly, that high-income countries have an higher odds ratio for mortality than low-income countries. Looking into this observation revealed that the rare nature of mucormycosis in developed countries has led to fewer physicians being trained to manage this disease differently from other, similar diseases. Moreover, physicians from low-income countries may be more likely to report patients who survive than deceased cases [51] . Difficulty in sample collection from deep tissues and low sensitivity of diagnostic tests leads to many cases remaining undiagnosed; thus, the actual prevalence of mucormycosis may be greater than that reported. According to the Leading International Fungal Education portal, which estimates the load of serious fungal infections worldwide, the yearly prevalence of mucormycosis may be ∼10,000 cases worldwide, excluding India. The estimate rises to in the blood and as protection from the immune system and antifungal agents [75] . Another study confirmed this finding and found that Rhizopus conidia stopped swelling inside the macrophages, so melanin is accumulated in the cell wall of the fungus. This melanin inhibits the phagosome maturation by continued induction of Akt/PI3K signaling [76] . The same effect of macrophages on germinating spores was observed in studying the effect of neutrophils, keeping in mind that neutrophils' effect on pathogens is different from that of macrophages. In general, neutrophils produce catatonic peptides, induce oxidative burst and activate an inflammatory state in the body. In the case of Rhizopus infection, it was observed that its germinating spores (swollen) produce chemotactic factors to recruit the neutrophils via complement activation but the resting spores do not [77] . As a result, the neutrophils produce cationic peptides Np1 and Np2 to kill the swollen spores of Rhizopus, and no effect was observed on resting spores (same as macrophages effect) [77] . The neutrophils respond as well to Rhizopus hyphae by inducing proinflammatory gene expression, such as TNF-a and IL-1b, which leads to damage of the hyphae, but this damage is lower than that encountered with other fungi such as A. fumigatus [78] . Some studies pointed out that the neutrophil response toward Rhizopus hyphae is impaired in hyperglycemia, which further increases the risk of diabetic patients to mucormycosis [79] . The hallmark of mucormycosis is angioinvasion and local thrombosis at site of infection. Also, Chang et al. reported that thrombocytopenia is a major risk factor for developing mucormycosis in organ transplant patients [80] . All of these findings point out that platelets may have an effect in defending the body against invasive mucormycosis. Perkhofer et al. found that the platelets adhere to both the fungal hyphae and germinating spores and stop their elongation and germination, respectively [81] . NK cells induce cell cytotoxicity to lessen tissue damage upon receiving signals from macrophages, dendritic cells or T cells through secretion of IL-12 and type-1 interferon (IFN) [65] . In case of mucormycosis, the NK cells' effect is highly pronounced toward Rhizopus hyphae not the conidia. The direct contact between the NK cells and the hyphae induce the production of perforin. However, it was found that the hyphae have immunosuppressive effects which decrease the production of IFN-γ and regulated on activation, normal T cell expressed and secreted (RANTES); CCL5 [82] . Although the role of adaptive immunity in fighting fungal infection is crucial, it plays a secondary role in case of Mucorales infection. Traditionally, T helper 1(T H1 ) produces IFN-γ to provide immunity against fungal infection but IL-4 produced by T H2 increases the susceptibility to infection. Moreover, IL-17 produced by subset of T H1 , T H17 , provides mucosal immunity against fungal infection. Furthermore, dendritic cells after recognizing β-glucan of the fungal cell wall produces IL-23, which allows the development of T H17 [83] . The activation of the pathway of IL-23/T H17 leads to induction of an inflammatory state in the body, which leads to neutrophils recruitment. In case of Rhizopus infection, its hyphae stimulates the production of IL-23 by dendritic cells [83] . Patients at high risk for mucormycosis are those having preexisting comorbidities such as uncontrolled diabetes mellitus (DM), DKA, lung diseases, ventilator-associated pneumonia, neutropenia or high iron levels [84] . Patients on deferoxamine [85] or having hematological malignancies such as leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, aplastic anaemia and sideroblastic anaemia [86, 87] , undergoing stem cell transplants or organ transplant patients are also at risk [88] . Patients who use corticosteroids, tocilizumab and iatrogenic immunosuppression [89, 90] may also develop mucormycosis. To a lesser extent, it was found that high doses of glucocorticoids can have a role in impairing the phagocytosis process and the intracellular killing of Mucorales spores [91] . There are other conditions that may increase the risk of developing mucormycosis, such as renal insufficiency, presenting with HIV or AIDS [92] , the use of contaminated medical tools near or at open wounds, open skin trauma including burns or other injuries or cuts in skin [93] . Extreme malnutrition, the use of illegal drugs that involve needles, as well as hepatitis or cirrhosis have all been associated with mucormycosis [94] . Mucormycosis has even invaded the pediatric population [95] . Additionally, premature newborns can be at higher risk to develop mucormycosis infection as well [96] . There are five major forms of infection that can be summarized as rhino-orbito-cerebral, pulmonary, gastrointestinal, cutaneous and disseminated infection, with the rhinocerebral presentation being the most common form [97] . The clinical manifestations of the rhino-orbital-cerebral form (which begins in the paranasal sinuses after the inhalation of Mucorales spores and expands to orbitals and brain tissues), include symptoms that are similar to complicated sinusitis, nasal blockage, headache, blackish or bloody nasal discharge, redness around the eyes and nose, facial pain with numbness, eye pain with blurry vision, ocular-motility changes, periorbital cellulitis, orbital inflammation and drooping eyelids [98] [99] [100] . Symptoms of intracranial invasion may present as neurological signs and altered mental status [101] . However, the patient may exhibit one or more of the listed signs and symptoms according to the severity of the disease [102] . The symptoms of the pulmonary type with the hyphal invasion of the pulmonary blood vessels include highgrade fever (>38 • C), accompanied by nonproductive cough and airway obstruction. If the invasion has reached the hilar blood vessels, a massive hemoptysis may be present [103, 104] . Meanwhile, the ingestion of the mucor spores may result in the gastrointestinal form of infection, which can show celiac, appendiceal, iliac or gastric perforation [105] . Surprisingly, the clinical manifestations of mucormycosis differs by epidemiology because different species inhabit different habitats, leading to different clinical profile. For instance, Saksenaea is predominant in North and South America and is known to cause cutaneous manfestations and, to a lesser extent, rhino-orbital symptoms. An interesting meta-analysis linking the epidemiology and clinical manifestation was studied recently [106] . The direct inoculation of the spores into the skin through trauma or burns in a susceptible host can show the clinical manifestations of the cutaneous form. This form of infection typically presents with black necrotic eschar and surrounding edema. The symptoms vary from localized disease to progressive fulminant disease. The latter may involve tissue gangrene and hematogenous dissemination [107, 108] . Finally, patients with profound iron overload, immunosuppression, neutropenia and active acute leukemia are the classic group of patients at risk for the disseminated form [84, [109] [110] [111] . The symptoms vary widely depending on the degree of dissemination and the vascular invasion [112] . The rapid dissemination of mucormycosis is believed to be an extraordinary phenomenon. A delay of only 12 h in the diagnosis can be lethal, and this is why 50% of the mucormycosis cases are diagnosed only in postmortem autopsy [113] . Chamilos et al. have shown that the delayed initiation of the treatment has resulted in twofold increase of mortality rate in the 12-week post-diagnosis assessment, compared with early treatment initiation (82.9% vs 48.6%) [114] . Indeed, a high index of suspicion is needed to make the appropriate diagnosis and initiate prompt treatment. The diagnosis can be categorized into probable infection, possible infection and proven infection. Probable infection of invasive mucormycosis includes the involvement of a host factor (presence of neutropenia, more than 3 weeks of corticosteroids, use of immunosuppressors, presence of hematological malignancies etc.), presence of a clinical criterion (imaging reveals lower respiratory tract infection, signs for sinusitis or sinonasal infection, bronchitis etc.), a mycological criterion by direct or indirect techniques (cytology, microscopy, culture, immune-detection of antigen or cell wall components). Possible infection of invasive mucormycosis includes cases that comply with both the criteria for a host factor and a clinical criterion [115] . Meanwhile, the diagnosis of a proven mucormycosis can be done through histopathologic, cytopathologic or direct microscopic investigation, illustrating the fungal hyphae (nonseptate or pauci-septate, of width of 6-16 μm) in the biopsy specimen, along with accompanied tissue damage, mycotic infiltration of blood vessels, or positive culture results [116] . Both focal bony erosions with the extrasinus spread are strongly indicative for the diagnosis of mucormycosis [56] . PCR could be the diagnostic modality for molecular identification of the organism [117] . The conventional radiological techniques are not specific for the diagnosis of mucormycosis. In contrast, the diagnosis of mucormycosis includes computed tomography (CT) of the chest; identifying the infiltrates that are not documented by the standard or regular radiograph [118] . The use of noncontrast CT of the paranasal sinuses is often the investigation of choice. MRI of orbit, brain and paranasal sinuses can assess the extent and the severity of disease [102] . In cases of intracranial or intraorbital spread, gadolinium-enhanced MRI is used [56] . To confirm the diagnosis of mucormycosis, laboratory methods for identification of the organisms and their culture are carried out [119] . Direct visualization of the organisms can be done by wet mount of KOH using bright microscope or fluorescent microscope after staining them with Blankophor and Calcofluor White fluorescent stains [120] . Morphologically, the hyphae of Mucorales are nonseptate rather than the septate hyphae of Aspergillum [119] . They have a characteristic ribbon-like structure with a pattern of branching from 45 • to 90 • . Mucorales hyphae are weakly stained with Gomori methenamine silver and periodic acid-Schiff techniques due to its thin wall [121] . These fungi grow normally on Sabouraud agar for 3-5 days at 25-30 • C. Microaerophilic conditions similar to infracted tissues are required when culturing Cunnighamella and Rhizopus [120] . There are many negative culture results despite positive microscopic identification due to possible mechanical damage of hyphae during preparation of the sample. However, better culture results were obtained at 37 • C [122] . Although Mucorales cause angioinvasion, the blood cultures are negative [123] . In case of neutropenic or immunocompromised hosts, the positive finding from the bronchoalveolar would suggest the presence of the infection and should mandate initiation of treatment [124, 125] . However, the histological examination of tissues from biopsies is the method of choice for the diagnosis. The invasion been seen on the histopathology is necessary to confirm the diagnosis with mucormycosis [126] . However, current diagnostic tools may fail to provide rapid results. Recently, there has been a trend for the use of rapid micro-culture assay strategies for early diagnosis of Mucorales infections caused by R. arrhizus directly in blood and tissue samples [127] . Early diagnosis and treatment is crucial because rapid progression of disease and higher mortality rate from intraorbital and intracranial complications can reach (50-80%) [128] . However, even with the prompt diagnosis and immediate treatment of the underlying diseases, along with the aggressive medical/surgical interventions, the management is still not fully effective. This eventually may lead to the spread of the infection and ultimately higher mortality rates [56] . Although the uncontrolled DM is a major risk factor for mucormycosis, diabetic patients may have a better outcome when it comes to rhino-orbito-cerebral mucormycosis than nondiabetic patients, as reported by Yohai et al. and Biltzer et al. [129, 130] ; those with leukemia and lymphoma, however, are believed to have poorer outcomes [94] . Starting with treating the patient's underlying medical condition and tapering the immunosuppressive agents are the first steps toward treatment. The mainstay of treatment is surgical removal of the infected parts along with the use of systemic antifungal agents. However, the choice of the proper antifungal agent seems to be limited because the Mucorales are inherently resistant to most popular and widely used antifungals [131, 132] . The treatment recommendations provided in this review are supported by the 2019 global guidelines for the diagnosis and treatment of mucormycosis, by the ECMM and the Consortium for Mycosis Education and Research [133] , providing more detailed guidance on management and alternative therapeutic options for mucormycosis [119] . The guidelines generally support prompt, early and complete surgical debridement of the infected area whenever possible. The start of a systemic antifungal treatment is crucial as well. There's a 1.5-fold increase in the survival rates when combining surgical interventions with early, high doses of systemic antifungal agents [114, 134] . Surgical approach alone was reported to be not curative; however, aggressive surgical interventions were shown to have better survival rate [57, 135] . According to the global guideline for the diagnosis and management of mucormycosis in 2019 [119] , the first-line antifungal monotherapy agent is liposomal amphotericin B, with a dose of 5-10 mg/kg/d. However, when substantial renal toxicity develops, a reduction in the dose can be done as necessary. When there is brain involvement or solid organ transplant, the dose should be 10 mg/kg/d, initiated from day 1. Doses below 5 mg/kg/d are marginally recommended [118, 136] . Doses up to 15 mg/kg/d were proven by Walsh et al., to be well tolerated [137] . Amphotericin B lipid complex with dose of 5 mg/kg/d is recommended in patients presented with CNS involvement [119] . Amphotericin B is a polyene that exerts its antifungal effect via binding to ergosterol, providing the structure and rigidity of the fungal cells. Amphotericin B forces the cell membrane to leak and eventually leads to cell death [138] . For decades, amphotericin B deoxycholate has been the drug of choice [4, 134] . Despite its effectiveness, its use was limited due to its substantial toxicity [139, 140] . Current guidelines recommend against its use with the exception of settings where there is no other available antifungal therapy. Triazoles, the largest class of antifungal agents in the clinical practice, can be added as well. They act on inhibiting the 14-α-demethylation, which in turn can lead to an increase in the toxic 14-α-methylsterols, the one that alters the permeability of the fungal membrane [141] . Isavuconazole, a broad-spectrum antifungal, with less hepatotoxcity than other mold-active azoles, has been licensed by USA as the first-line treatment of mucormycosis [142] . The approved dose for isauvoconazole as a treatment for mucormycosis is 3 × 200 mg to be given for day 1-2, and 1 × 200 mg to be given from day 3. A dose of 372 mg of isavuconazonium sulfate (the currently available prodrug form of isauvoconazole) is equivalent to 200 mg isavoconazole [143] . Isavoconazole is also strongly recommended as salvage treatment with proven activity in clinical scenarios, refractory disease, intolerance or toxicity [143, 144] . Posaconazole, a second-generation triazole, is advised to be used prophylactically in high-risk patients such as neutropenic patients or those with grafts. Posaconazole is considered as a salvage therapy for patients who cannot withstand or intolerant to the amphotericin B [145] . Until recently, posaconazole was only provided in suspension form for the management of invasive fungal infections with respect to the long-term use. Unfortunately, the suspension form has displayed variable pharmacokinetics. Drug concentration was reported to be less than predicted at the target site [141] . However, the introduction of delayed-release tablet form of posaconazole has succeeded to address most of the absorption concerns The dose of posaconazole's tablet for the treatment of fungal infections is 300 mg orally twice on the first day, followed by 300 mg orally once daily, regardless of food timing [60] . The intravenous formulation can be provided for oral intolerant patients; the dosing regimen is the same as the delayed-release formulation. The use of combination therapy can be under the umbrella of lack of enhanced toxicity with possible but unproven added benefit. There is no definitive data to guide the use of antifungal combination therapies, and they are kept as marginal recommendation. However, the use of combination antifungal agents was addressed in large number of studies. Although the echinocandins have no inherent activity against mucormycosis, some evidence suggests that echinocandins may augment the polyene therapy. The benefit of adding the echinocandins is to provide a polyene backbone that enhances and augments therapy. They are believed to inhibit the β-1, 3-glucan, a cell-wall component [146] . In a retrospective review of two institutions, enhanced outcomes were shown by the use of a combination of polyene-caspofungin therapy in rhino-orbital and rhino-orbital-cerebral patients, compared with polyene-only therapy [147] . On the other hand, the use of deferosirox (iron chellator) with liposomal amphotericin B revealed a higher mortality rate of patients at day 90, hence, it is not recommend to use adjunctive deferasirox as a part of initial combination regimen [147] . Hyperbaric oxygen has been proposed as a beneficial adjunctive treatment for mucormycosis, especially in patients with diabetes [148] . High concentration of oxygen has a fungicidal activity and can inhibit the growth of Mucorales in vitro [149] . It can also improve the neutrophil activity, supply better flow of oxygen to ischemic tissues and improve wound healing [148, 150, 151] . In a previous study, the use of standard therapy of mucormycosis had a 22% survival rate compared with 83% survival rate in patients who have received standard therapy with hyperbaric oxygen [150] . However, the use of hyperbaric oxygen is limited due to its only experimental and limited clinical data. Both interferon and granulocyte-macrophage colony-stimulating factor act as enhancers to the granulocytes' ability to damage the Mucorales [152] . The treatment with recombinant granulocyte colony-stimulating factor (G-CSF) has been used in combination with lipid amphotericin B, showing promising outcomes [153] [154] [155] . The use of G-CSFmobilized granulocyte transfusions has been used in refractory mycoses, including mucormycosis [156] . However, data regarding their use is limited. Unfortunately, despite aggressive surgical intervention and the use of systemic antifungals, poor prognosis and high mortality rates (33.8-80%) has been reported in disseminated infections [157, 158] . Unfortunately, mucormycosis can lead to eyes and upper jaw loss. Patients should be psychologically prepared to face and accept the loss of function that comes, for example, with a missing jaw, as chewing problems, swallowing difficulties and facial aesthetics. In patients who lose their eyes or upper lip, mechanical substitution or prosthetic constructions are considered to be options. COVID-19 continues to cause significant fatalities worldwide. Until the emergence of an effective antiviral therapy, glucocorticoids have proved to play essential roles in COVID-19 management -namely, reducing mortality in hypoxemic COVID-19 patients [159] . Yet the extensive use of steroids/monoclonal antibodies such as tocilizumab/broad-spectrum antibiotics together with the virus immune dysregulation may all together exacerbate previous fungal diseases and can upsurge the danger of secondary infections in COVID-19 patients [160] [161] [162] [163] . Although previously of low incidence rate, numerous mucormycosis cases have been reported recently as a consequence of the COVID pandemic, leading to a substantial rise in its incidence [164] . Unfortunately, a definite correlation between COVID-19 and elevated mucormycosis infections is obvious. For example, a teaching hospital in India has reported 23 cases of sinus mucormycosis in only 4 months, with all patients being COVID-19 positive [165] . Mehta and Pandey reported a case of COVID-19 associated rhino-orbital mucormycosis in September 2020 [160] . Another report was issued by Werthman-Ehrenreich that month [164] . In another study, Garg et al. reported three subjects with COVID-19-associated mucormycosis lacking the traditional risk factors, such as DM, transplantation or hematological malignancies, which was one worrying finding. The development of mucormycosis was probably due to the use of glucocorticoids and hence, the utilization of higher doses of glucocorticoids should be prevented [166] . Steroid therapy indeed appears to be a double-edged sword, predisposing patients to secondary bacterial and invasive fungal infections, thus impacting morbidity and mortality [167] . Pandiar et al. recently hypothesized that the COVID-19 generates an environment for proliferation of Mucorales and consequent mucormycosis. In their study, they proposed a new hypothesis for the incidence of mucormycosis with scientific proof that explains dysregulation of ACE-2 expression in lungs and several tissues and how this results in a cascade of pathways that creates a suitable milieu for mucormycosis. Hence, COVID-19 infected patients are at a higher risk of contracting mucormycosis [168] . In a new systematic review carried out through 13 May 2021, 101 cases of COVID-19-associated mucormycosis have been reported, including 82 cases from India and 19 from elsewhere. Mucormycosis was principally perceived in males (78.9%). Hyperglycemia at presentation was the central predisposing factor detected in most cases (83.3%), followed by cancer (3.0%). Preexisting DM accounted for 80% of cases, while associated DKA was present in ∼15% of cases. Steroid intake was reported in 76.3% of cases, followed by remdesivir (20.6%). The most common organ involved with mucormycosis was nose and sinus (88.9%), followed by rhino-orbital (56.7%) and ROCM type (22.2%). Total mortality was recorded as 30.7% of the cases. Jointly, these observations imply that COVID-19, diabetes and steroids is a dreadful triad in mucormycosis patients [169] . In addition, this study revealed the serious problem facing India. Rising cases of COVID-19 associated mucormycosis especially in India may be due to the very high incidence rate of type 2 diabetes and the large proportion of people who do not receive health care or do not undergo diagnostics. Moreover, their overloaded hospitals further enhance the spread of mycoses. In this review, we have reported the appearance of additional COVID-19 associated mucormycosis cases from India. A few days ago, Krishna et al. reported a post-COVID-19 patient in India, who was an uncontrolled type 2 diabetic male and was diagnosed with mucormycosis of the right maxilla [39] . Nehara et al. reported the first case series of COVID-19 associated mucormycosis patients from India consisting of five cases of COVID-19 infection, who developed rhino-orbital mucormycosis during their treatment [170] . Numerous other cases are being described in electronic media in different countries, however, not officially reported. Indeed, the situation in India is critical, where both COVID-19 and mucormycosis are considered a double health threat to their healthcare system. The use of corticosteroids in COVID-19 patients with diabetes mellitus is lifesaving [171] . On the other hand, it makes the room for worsening the diabetic control, creating the ultimate environment for opportunistic infections such as mucormycosis. Adding to the immunosuppressant nature of glucocorticoids they may also provide another foothold for invasion [172] . Proper glycemic control, wise use of glucocorticoids, prompt antifungal treatment with proper surgical debridement are the recommended patterns for management [7] . A sum of factors may trigger mucormycosis in COVID-19 patients. The principal reason enabling Mucorales spores to propagate in COVID-19 individuals is a perfect setting of hypoxia. COVID-19 also leads to endothelialitis, endothelial damage, thrombosis, lymphopenia and reduction in Mucorales-specific T cells (CD4+ and CD8+). These T cells produce cytokines including IL-4, IL-10 IL-17 and IFN-γ, which impair the fungal hyphae thus their reduction predisposes to secondary fungal infection [173] . In addition, the existence of DM or DKA intensifies the danger of developing mucormycosis due to hyperglycemia and because it aggravates COVID-19 severity. Steroid therapy to treat COVID-19 can also cause hyperglycemia, even in healthy individuals, and cause steroid induced diabetes. In addition, steroid therapy together with DM can enhance immunosuppression and hyperglycemia, elevating the infection risk [174] . DKA is also often detected due to steroid consumption. Decreased pH caused by acidosis creates a suitable media for mucor spores germination. Further, steroids decrease the phagocytic activity of white blood cells and impair bronchoalveolar macrophages migration and ingestion, making the diabetic patient extremely susceptible to mucormycosis [169] . Furthermore, hyperglycemia results in glycosylation of transferrin and ferritin, which decreases iron binding, providing free available iron as an ideal resource for mucormycosis. Increased cytokines such as IL-6 also increases free iron by increasing ferritin levels due to increased synthesis and decreased iron transport. Acidosis further increases free iron by the same mechanism and also decreases the transferrin ability to chelate iron [175] . Finally, lengthy hospital stays with or without mechanical ventilators may also predispose to the development of mucormycosis. It is recommended to avoid the extensive overzealous use of steroids and wide-spectrum antibiotics in the treatment course of COVID-19. SARS-CoV-2 spikes glycoproteins were recently investigated for designing potential antiviral targets [175] ; however, drugs targeting immune pathways (e.g., tocilizumab) should be prevented if not clearly beneficial. These agents should be monitored to achieve their therapeutic response at the lowest dose, and over the shortest duration possible. As there is a growing evidence about confirmed new cases of mucormycosis that has been linked to COVID-19, there is a need for better awareness regarding the importance of early identification, fast diagnosis and prompt treatment initiation, which may significantly reduce the morbidity and mortality rates. However, a major obstacle faced by clinicians is how to choose among the current available antifungal agents in the treatment of COVID-19-associated mucormycosis given the lack of active clinical trials. For efficacious management of mucormycosis, synchronized tasks from an integrative group including infectious diseases, ophthalmology, neurosurgery, otorhinolaryngology, pathology and microbiology sections are vital. The Indian Council of Medical Research has suggested that doctors should carry out basic tests such as sinus tenderness, vision and ocular motility in the physical assessment of severely ill or diabetic COVID-19 patients or those using steroids. Particular care should be given to patients showing mucormycosis signs including one-sided nasal obstruction or headache, sinus pain, swelling, numbness or toothache [176] . It is important to spread awareness among both the healthcare system and the general public regarding how serious and fatal the mucormycosis infection is. It is crucial to educate the patients to report their symptoms as early as possible so they can help the healthcare team to have prompt onset of diagnosis of the infection. COVID-19 patients or those who have just recovered from COVID-19 infection should try not expose themselves to any of the natural habitats of the fungus. Mass vaccination against COVID-19 will also help to reduce the probability of severe or secondary complications. Hospitals have to ramp up their hygiene level, preventing the onset of damp areas that might be a breeding ground for mucormycosis. Caution should be taken particularly when dealing with oxygen cylinders, ventilators, and breathing pumps. Mucormycosis seems to be associated with the COVID-19 pandemic and role of the immune response in disease progression. The extensive use of steroids and wide spectrum antibiotics in the treatment course of COVID-19 should be avoided or at least closely monitored. Drugs targeting immune pathways should be prevented if not clearly beneficial and they should be monitored to achieve their therapeutic response at the lowest dose. There is a growing evidence about confirmed new cases of mucormycosis that has been associated with COVID-19. There is a need for better awareness regarding the importance of early identification, fast diagnosis and prompt treatment initiation of mucormycosis particularly, under the lack of active clinical trials. The collection of epidemiological data is important for taking appropriate and affordable measures against mucormycosis infection. Guidelines should be developed and implemented in all healthcare facilities to enable epidemiological data collection and rapid reporting of any outbreaks. Antifungal agents stewardship programs should be implemented for antifungal prescription and use as well as for the control and monitoring of infections caused by the clinically relevant pathogens in healthcare facilities. Rational use of corticosteroids as well as immunosuppressive agents should be undertaken and monitored. Alternative approaches for treating such infections should be considered, such as phage therapy or promising combination of antifungal agents. Finally, strict and protective measures must be taken to prevent dessimanation of this life-threatenging fungal pathogen. • Mucormycosis seems to be associated with the COVID-19 pandemic. • Historical records, taxonomy and epidemiology of mucormycosis are illustrated here. • There are multiple risk factors of mucormycosis; patients with comorbidities or having hematological malignancies are on the top of the list. • There are five major forms of infection that can be summarized as rhino-orbito-cerebral, pulmonary, gastrointestinal, cutaneous and disseminated infection, with the rhinocerebral presentation being the most common form. • Early diagnosis and treatment is crucial. • Steroid therapy appears to be a double-edged sword in the era of COVID-19. • COVID-19 associated mucormycosis in now creating an epidemic in a global pandemic, particularly in the low-to middle-income countries. • It is important to spread the awareness among both healthcare system and general public regarding how serious and fatal the mucormycosis infection is. MG Alshahawey, GS El-Housseiny, NS Elsayed reviewed the literature and drafted the manuscript. MY Alshahrani, LM EL Wakeel, KM Aboshanab reviewed and edited the manuscript. All authors read and approved the manuscript. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript. This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit http://creativecomm ons.org/licenses/by/4.0/ Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: a single-centered, retrospective study SARS-CoV-2 virus isolated from the mastoid and middle ear: implications for COVID-19 precautions during ear surgery Emerging invasive fungal infections in critically ill patients: incidence, outcomes and prognosis factors, a case-control study Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates Mucormycosis and COVID-19 an epidemic in a pandemic? ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low-and middle-income countries Frequency of occurrence, seasonal variation and antifungal susceptibility of opportunistic Mucorales isolated from hospital soils in Iran Zygomycetes in human disease Black fungi: clinical and pathogenic approaches Archiv für pathologische Anatomie und Mycosis mucorina. Archiv für pathologische Anatomie und Mucormycosis -a new disease? Increasing incidence of zygomycosis (mucormycosis), France Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus Mucormycosis -from the pathogens to the disease Updates on the taxonomy of Mucorales with an emphasis on clinically important taxa A higher-level phylogenetic classification of the Fungi Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives A phylum-level phylogenetic classification of zygomycete fungi based on genome-scale data Fungal sinusitis Species recognition and clinical relevance of the zygomycetous genus Lichtheimia (syn. Absidia pro parte, Mycocladus) A revised species concept for opportunistic Mucor species reveals species-specific antifungal susceptibility profiles DNA barcoding in Mucorales: an inventory of biodiversity Diversity and delimitation of Rhizopus microsporus Disseminated Cunninghamella bertholletiae infection with spinal epidural abscess in a kidney transplant patient: case report and literature review Necrotizing fungal infection due to Saksenaea erythrospora: a case report and review of literature Epidemiology and outcome of zygomycosis: a review of 929 reported cases The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports A global analysis of Mucormycosis in France: the RetroZygo Study Prospective antifungal therapy (PATH) alliance: focus on mucormycosis Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors Increasing incidence of mucormycosis in University Hospital Mucormycosis in Iran: a six-year retrospective experience Mucormycosis in Iran: a systematic review Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment Ten years' experience in zygomycosis at a tertiary care centre in India Invasive zygomycosis in India: experience in a tertiary care hospital Epidemiology and burden of invasive fungal infections in the countries of the Arab League Burden of fungal infections in Qatar Burden of serious fungal infections in Jordan Mucormycosis: an 8-year experience of a tertiary care centre in Saudi Arabia Mucormycosis in hospitalized patients at a tertiary care center in Lebanon: a case series Egypt: review of 10 reported cases Overview and outcome of mucormycosis among children with cancer: Report from the Children's Cancer Hospital Egypt Mucormycosis in the Middle East and North Africa: analysis of the FungiScope registry and cases from the literature COVID-19-associated mucormycosis (CAM): case-series and global analysis of mortality risk factors Global and multi-national prevalence of fungal diseases -estimate precision Epidemiology of mucormycosis in India Global epidemiology of mucormycosis Epidemiology of mucormycosis in India Mucormycosis of the head and neck: report of five cases with different presentations Rhinocerebral mucormycosis in patients without predisposing medical conditions: a review of the literature Novel perspectives on mucormycosis: pathophysiology, presentation, and management National Organization for Rare Disorders (NORD) Breaking the mold: a review of mucormycosis and current pharmacological treatment options • This reference has helped us throughout the manuscript, providing a detailed pharmacological options for the mucorpycosis Misfortune never comes alone-the new 'black fungus' accompanying COVID-19 wave Host cell invasion in mucormycosis: role of iron Pulmonary defense mechanisms against opportunistic fungal pathogens Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus Innate and adaptive immunity to mucorales Necrotizing cutaneous mucormycosis after a Analysis of a food-borne fungal pathogen outbreak: virulence and genome of a Mucor circinelloides isolate from yogurt Molecular mechanisms of mucormycosis -the bitter and the sweet The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice CotH3 mediates fungal invasion of host cells during mucormycosis Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of rhizopus microsporus In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus Human and rat macrophages mediate fungistatic activity against Rhizopus species differently: in vitro and ex vivo studies Virulent strain of Lichtheimia corymbifera shows increased phagocytosis by macrophages as revealed by automated microscopy image analysis Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species Neutrophil chemotactic responses induced by fresh and swollen Rhizopus oryzae spores and Aspergillus fumigatus conidia Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through Toll-like receptor 2 induction but display relative resistance to oxidative damage Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, and role of endogenous thrombopoietin Potential antifungal effects of human platelets against zygomycetes in vitro Rhizopus oryzae hyphae are damaged by human natural killer (NK) cells, but suppress NK cell mediated immunity Generation of IL-23 producing dendritic cells (DCs) by airborne fungi regulates fungal pathogenicity via the induction of TH-17 responses Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment Mucormycosis: association with deferoxamine therapy Successful treatment of rhinocerebral zygomycosis using liposomal nystatin Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion Successful treatment of mucor infection after liver or pancreas-kidney transplantation Pulmonary mucormycosis: the last 30 years Zygomycosis in the 1990s in a tertiary-care cancer center Glucocorticoids and invasive fungal infections Aquatic sports dermatoses: part 3 on the water Disseminated mucormycosis in immunocompromised children: are new antifungal agents making a difference? A multicenter retrospective study National Organization for Rare Disorders Cutaneous mucormycosis: report of five cases and review of the literature Invasive fungal disease of the sinus and orbit: a comparison between mucormycosis and Aspergillus Clinical features and outcome of mucormycosis Epidemiology and antifungal susceptibilities of Mucoralean fungi in clinical samples from the United States Disease entities in mucormycosis Spectrum of MR imaging findings of sinonasal mucormycosis in post COVID-19 patients Invasive pulmonary mucormycosis with concomitant lung cancer presented with massive hemoptysis by huge pseudoaneurysm of pulmonary artery Fungal infection by Mucorales order in lung transplantation: 4 case reports Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports Epidemiology and clinical manifestations of mucormycosis Disseminated zygomycosis: report of four cases and review Iron overload is a risk factor for zygomycosis Successful treatment of prosthetic aortic value mucormycosis Cutaneous mucormycosis and motor vehicle accidents: findings from an Australian case series The clinical presentation and diagnosis of invasive fungal infections Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group Challenges in the diagnosis and treatment of mucormycosis Detection and identification of fungal pathogens in blood by using molecular probes Mucormycosis in hematologic malignancies: an emerging fungal infection Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium • This reference is the updated global guideline for the diagnosis and management of mucormycosis Laboratory diagnosis of mucormycosis: current status and future perspectives Histologic features of zygomycosis: Emphasis on perineural invasion and fungal morphology Increased culture recovery of zygomycetes under physiologic temperature conditions Current status of diagnosis of mucormycosis: update on molecular methods The role of BAL in the diagnosis of pulmonary mucormycosis Cure of pulmonary Rhizomucor pusillus infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases Rapid and low-cost culture-based method for diagnosis of mucormycosis using a mouse model An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient Survival factors in rhino-orbital-cerebral mucormycosis Patient survival factors in paranasal sinus mucormycosis In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between Recent advances in the management of mucormycosis: from bench to bedside Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study Quantifying membrane permeability of amphotericin B ion channels in single living cells Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia Posaconazole levels in patients taking the delayed-release tablet versus the oral suspension: a retrospective comparison Molecular approaches to the study of Coccidioides immitis Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species Antifungal agents: mechanisms of action Caspofungin inhibits Rhizopus oryzae 1, 3-β-d-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis The Deferasirox-AmBisome therapy for mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial Hyperbaric oxygen as an adjunctive treatment for zygomycosis Fungal sinusitis: progression of disease in immunosuppression -a case report Diabetic ketoacidosis and rhino-orbital mucormycosis Invasive fungal rhinosinusitis Interferon-γ and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor Interferon-γ and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children Cytokines as therapy for opportunistic fungal infections Secondary prophylaxis of invasive fungal infections with combination antifungal therapy and G-CSF-mobilized granulocyte transfusions in three children with hematological malignancies Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis Rhinocerebral mucormycosis: consideration of prognostic factors and treatment modality Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis Rhino-orbital mucormycosis associated with COVID-19 Predictors and outcomes of healthcare-associated infections in COVID-19 patients A fatal case of Rhizopus azygosporus pneumonia following COVID-19 Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy Mucormycosis with orbital compartment syndrome in a patient with COVID-19 Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum Coronavirus disease (COVID-19) associated mucormycosis (CAM): case report and systematic review of literature The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis Does COVID 19 generate a milieu for propagation of mucormycosis? Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India COVID-19 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India COVID19: Dexamethasone; death or deliverer therefrom? COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? Study on invasive aspergillosis using galactomannan enzyme immunoassay and determining antifungal drug susceptibility among hospitalized patients with hematologic malignancies or candidates for organ transplantation Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases Mucormycosis -a serious threat in the COVID-19 pandemic?